WCLC 2018

Presidential Symposium – Top 5 abstracts

Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Presented By

Dr Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, USA

Trial

Phase 3, PACIFIC

Conference

WCLC 2018

21 November, 2018 23:28

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Presented By

Dr Ross Camidge, University of Colorado Cancer Center, USA

Trial

Phase 3, ALTA-1L

Conference

WCLC 2018

21 November, 2018 22:31

Benefits of chest CT screening

Presented By

Prof. Harry de Koning, Erasmus Medical Center, the Netherlands

Trial

NELSON

Conference

WCLC 2018

21 November, 2018 21:33

New standard of care in extensive-stage small-cell lung cancer

Presented By

Dr Stephen Liu, Georgetown University Hospital, USA

Trial

IMpower133

Conference

WCLC 2018

21 November, 2018 20:55

No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype

Presented By

Prof. Giorgio Scagliotti, University of Turin and San Luigi Hospital, Italy

Trial

LUME-Meso

Conference

WCLC 2018

21 November, 2018 19:58

New Aspects of Immunotherapy

Next generation immunotherapy in non-small-cell lung cancer

Presented By

Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland

Conference

WCLC 2018

21 November, 2018 23:02

Combination therapies: Where are we in 2018?

Presented By

Prof. Martin Reck, German Center for Lung Research, Germany

Conference

WCLC 2018

21 November, 2018 22:05

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer

Presented By

Prof. Balazs Halmos, Albert Einstein College of Medicine and Montefiore Medical Center, USA

Trial

Phase 3, KEYNOTE-407

Conference

WCLC 2018

21 November, 2018 21:18

New Aspects of Targeted Therapy

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib

Presented By

Prof. Suresh Ramalingam, Emory University School of Medicine, Winship Cancer Institute, USA

Trial

Phase 3, FLAURA

Conference

WCLC 2018

21 November, 2018 23:21

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Conference

WCLC 2018

21 November, 2018 22:24

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative

Conference

WCLC 2018

21 November, 2018 21:28

Mesothelioma

Unmet needs in surgical management of malignant pleural mesothelioma

Presented By

Dr Valerie Rusch, Dr Harvey Pass,

21 November, 2018 23:31

Angiogenic and stromal biomarkers in malignant mesothelioma

Conference

WCLC 2018

21 November, 2018 22:40

Advanced Non-small Cell Lung Cancer

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Trial

Phase 3, CheckMate 227

Conference

WCLC 2018

21 November, 2018 23:44

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Trial

Phase 3, JAVELIN Lung 200

Conference

WCLC 2018

21 November, 2018 22:46

Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer

Trial

Phase 3, ARCHER 1050

Conference

WCLC 2018

21 November, 2018 21:49

Novel Therapies in ROS1 and EGFR

Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement

Conference

WCLC 2018

21 November, 2018 23:51

Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cance

Conference

WCLC 2018

21 November, 2018 22:53

Entrectinib treatment in patients with ROS1+ NSCLC

Trial

STARTRK-2, STARTRK-1, ALKA-372-001

Conference

WClC 2018

21 November, 2018 21:57

Advances in Small-cell and Neuroendocrine Tumours